Side-by-side · Research reference

CrystagenvsKPV

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BAnimal-StrongAUTO-DRAFTED13/39 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

01Mechanism of Action

Parameter

Crystagen

KPV

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

No melanocortin receptor binding

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

KPV

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

200–500 mcg / day SQ or oralDalle-Pang 2024

Evidence basis

Animal / mechanistic

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

Daily or 2–3× per week

Duration

Unknown — chronic administration presumed in animal models

4–8 weeks per cycle

Half-life

Not reported

Hours (estimated; rapid tissue uptake)

Lower / starter dose

—

100 mcg / day

Reconstitution

—

Bacteriostatic water (SQ form)

Timing

—

No specific time; often taken with / before meals (oral)

04Side Effects & Safety

Parameter

Crystagen

KPV

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Injection site reaction

—

Mild irritation

GI symptoms

—

Rare nausea (oral form)

Pigmentation

—

None (unlike full α-MSH)Dalle-Pang 2024

Long-term safety

—

Limited human data

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

KPV

·Pregnancy / breastfeeding

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

KPV

·Active autoimmune disease (theoretical)

05Administration Protocol

Parameter

Crystagen

KPV

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Add 1 mL bacteriostatic water to vial per labelling.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Morning preferred; oral form taken with / before meals.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G insulin syringe (SQ form).

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018